BofA Securities analyst Alec Stranahan maintains $Recursion Pharmaceuticals (RXRX.US)$ with a hold rating, and adjusts the target price from $12 to $10.
According to TipRanks data, the analyst has a success rate of 42.3% and a total average return of -7.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Recursion Pharmaceuticals (RXRX.US)$'s main analysts recently are as follows:
While political and rate uncertainties persist as concerns, the overall condition of the Biopharma sector is seen as greatly enhanced from its lows in 2022. Among the stocks evaluated, preference is given to those in later-stage clinical trials or early launch phases; however, there's a growing investor interest in Phase 1 clinical programs that present near-term catalysts and data which reduce risks.
Healthcare technology stocks were generally under pressure for most of last year but witnessed a recovery in the last two months following the election. Coupled with cuts to consensus estimates since mid-last year, there appears to be attractive buying opportunities in the sector for 2025. Analysts believe that companies with robust balance sheets and consistent free cash flow profiles will face less risk of multiple contraction, despite potentially modest growth trends. On the contrary, the greatest risk is perceived for companies that have strained balance sheets and limited profitability prospects in both the near and longer term.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美银证券分析师Alec Stranahan维持$Recursion Pharmaceuticals (RXRX.US)$持有评级，并将目标价从12美元下调至10美元。
根据TipRanks数据显示，该分析师近一年总胜率为42.3%，总平均回报率为-7.1%。
此外，综合报道，$Recursion Pharmaceuticals (RXRX.US)$近期主要分析师观点如下：
尽管政治和利率的不确定性仍然令人担忧，但生物制药行业的整体状况被认为已从2022年的低点大幅改善。在评估的股票中，优先考虑处于后期临床试验或早期启动阶段的股票；但是，投资者对提供短期催化剂和数据以降低风险的1期临床项目的兴趣与日俱增。
在去年的大部分时间里，医疗保健科技股普遍承压，但在大选后的最后两个月中出现了复苏。再加上自去年年中以来对共识预期的下调，该行业在2025年似乎有吸引力的买入机会。分析师认为，尽管增长趋势可能不大，但拥有强劲资产负债表和稳定的自由现金流状况的公司面临的多重收缩风险将降低。相反，对于资产负债表紧张且短期和长期盈利前景有限的公司来说，风险最大。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
